A Phase 2/3 interventional study of nab-Paclitaxel and Carboplatin in Breast Tumor, Breast Cancer and Cancer of the Breast, sponsored by Celgene. Completed at 140 sites in 12 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-02-21.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms — 7 open to participants now, 9 under way, none of them phase 3. Albumin-Bound Paclitaxel · Triple Negative Breast Neoplasms.
Among the 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms, this one is the 4th largest by enrollment, is the only one that started in 2013, is one of 2 in phase 2/3, and was the 5th registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →7 of the 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Zhejiang Cancer Hospital · Sites in China
Ages 18–70 · Women only
Fudan University · Sites in China
Ages 18–70 · Women only
Fujian Cancer Hospital · Sites in China
Ages 18–75 · Women only
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–70 · Women only
Hebei Medical University Fourth Hospital · Sites in China
Ages 18–70 · Women only
By country, each count listing its studies:
Albumin-Bound Paclitaxel: first FDA approval 2005 (ABRAXANE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 20 · Phase 3 3
First in 2007; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 191 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 64 across the 25 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
Bristol-Myers Squibb has 8 studies filed under Triple Negative Breast Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06538896Zhejiang Cancer HospitalTislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis,an Exploratory, Single-Arm, Multicenter Phase II Clinical Study | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 25 studies testing Albumin-Bound Paclitaxel in Triple Negative Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects with triple negative metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer.
ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will compare the safety and efficacy of weekly nab-paclitaxel in combination with gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line therapy in female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human epidermal growth factor receptor 2 (HER2) negative (triple negative) metastatic breast cancer (TNMBC) or metastatic triple negative breast cancer. In the phase 2 portion of the study, the combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus carboplatin will be evaluated, and a comparator arm of gemcitabine combined with carboplatin will be used. In the phase 3 portion of the study, the selected nab-paclitaxel combination treatment will be compared to gemcitabine combined with carboplatin to evaluate progression free survival, safety and tolerability, overall survival, disease control rate and duration of response in women with metastatic triple negative breast cancer.
Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.
This study's enrollment of 191 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Browse Triple Negative Breast Neoplasms studies →Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
First submitted before Celgene became part of Bristol-Myers Squibb.
Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: A subject will be eligible for inclusion in this study only if all of the following criteria are met:
Pathologically confirmed as triple negative, source documented, defined as both of the following
Subjects must have received prior or neoadjuvant anthracycline therapy; unless (a) anthracycline treatment was not indicated or was not the best treatment option for the subject in the opinion of the treating physician; and (b) anthracycline treatment remains not indicated or, in the opinion of the treating physician, is not the best treatment option for the subject's metastatic disease.
a. Newly diagnosed subjects presenting with TNMBC are eligible for the study if anthracycline treatment is not indicated or is not the best treatment option for the subject in the opinion of the treating physician.
Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at least 6 months before randomization with all related toxicities resolved, and documented evidence of disease progression per RECIST 1.1 guidelines is required.
a. If prior neoadjuvant or adjuvant chemotherapy contained taxane, gemcitabine, or platinum agents, the treatment must have completed at least 12 months before randomization
Subject has the following blood counts at screening:
Subject has the following blood chemistry levels at screening:
Females of [defined as a sexually mature women who (1) have not undergone hysterectomy (the surgical removal of the uterus) or bilateral oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally for at least 24 consecutive months (i.e., has had menses at any time during the preceding 24 consecutive months)] must:
Exclusion Criteria:
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Treatment Arm A: nab-Paclitaxel 125 mg/m\^2 by intravenous (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day cycle by IV administration over 30 minutes
Drug: nab-Paclitaxel · Drug: Gemcitabine
Treatment Arm B: nab-Paclitaxel 125 mg/m\^2 on Days 1 and 8 by IV administration followed by carboplatin at an Area Under the Curve (AUC) of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Drug: nab-Paclitaxel · Drug: Carboplatin
Treatment Arm C: Gemcitabine 1000 mg/m\^2 on Days 1 and 8 by IV administration followed by carboplatin AUC 2 on Days 1 and 8 of each 21-day cycle by IV administration
Drug: Carboplatin · Drug: Gemcitabine
nab-Paclitaxel 125 mg/m\^2 by IV administration over 30 minutes on Days 1 and 8 of each 21-day treatment cycle.
Also known as: Abraxane
Carboplatin at an AUC of 2 on Days 1 and 8 of each 21-day cycle by IV administration
Also known as: Paraplatin,, Paraplatin AQ
Gemcitabine 1000 mg/m\^2 on Days 1 and 8 of each 21-day treatment cycle.
Also known as: Gemzar
Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment.
PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir.
Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment.
Percentage of participants with an Objective Complete or Partial Overall Response according to RECIST 1.1 and defined as: Complete response-disappearance of all target lesions; partial response at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.
Time frame: Disease response was assessed every 6 weeks; from date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy
The percentage of participants who initiated Cycle 6 receiving doublet combination therapy regardless of the need for dose modifications.
Time frame: Cycle 6
Kaplan-Meier Estimates of Overall Survival
Overall survival was defined as the time from the date of randomization to the date of death (from any cause).
Time frame: From date of randomization to data cut-off date of 16 December 2016; total length of time on study was 31 months for Arm A, 34 months for Arm B and 35 months for Arm C
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Treatment-emergent adverse events (TEAEs) were defined as any AEs that began or worsened with the onset date on or after the date of the first dose of IP through 28 days after the last dose. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on the participant's symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity as follows: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death.
Time frame: From randomization through to 28 days after the last dose of IP; up to data cut off date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Percentage of Participants Experiencing Dose Modifications (Reductions and Interruptions)
The number of participants with dose modifications occurring during the treatment period. Dose reductions and interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.
Time frame: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs
Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen with an onset date on or after the date of the first dose of IP through 28 days after the last dose.
Time frame: From randomization through to 28 days after the last dose of IP; up to data-cut off of date of 16 Dec 2016; maximum treatment duration of study drug exposure was 108.3 weeks for Arm A, 83 weeks for Arm B, 110.1 weeks for Arm C
This multicenter study was conducted by investigators in 11 countries in North America, Europe, Australia and South America, and enrolled participants at a total of 86 sites. Due to changes in the treatment landscape since the initiation of this trial, the decision was made not to proceed to the Phase 3 portion of the study.
| Milestone | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| Started | 61 | 64 | 66 |
| Safety population | 60 | 64 | 64 |
| Treatment discontinued | 60 | 64 | 64 |
| Completed | 0 | 0 | 0 |
| Not completed | 61 | 64 | 66 |
| Withdrew: Death | 2 | 0 | 1 |
| Withdrew: Adverse event | 9 | 13 | 12 |
| Withdrew: Progressive disease | 31 | 35 | 36 |
| Withdrew: Symptomatic deterioration | 3 | 3 | 1 |
| Withdrew: Withdrawal by subject | 6 | 4 | 6 |
| Withdrew: Physician decision | 4 | 3 | 6 |
| Withdrew: Non-compliance with study drug | 1 | 2 | 0 |
| Withdrew: Given commercially available drug | 0 | 0 | 2 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Withdrew: Miscellaneous | 3 | 3 | 0 |
| Withdrew: Untreated: other | 0 | 0 | 1 |
| Withdrew: Untreated: death | 0 | 0 | 1 |
| Withdrew: Untreated: withdrawal before study start | 1 | 0 | 0 |
PFS was defined as the time from the date of randomization to the date of disease progression or death from any cause on or prior to the data cutoff date for the statistical analysis, whichever occurred earlier. Tumor responses were assessed every 6 weeks using, Response Evaluation Criteria in Solid Tumors (RECIST 1.1) and defined as: Complete response (CR) is the disappearance of all target lesions; Partial response (PR) occurs when at least a 30% decrease in the sum of diameters of target lesions from baseline; Stable disease is neither sufficient shrinkage to qualify for a PR nor sufficient increase of lesions to qualify for Progressive disease (PD); Progressive Disease- is at least a 20% increase in the sum of diameters of target lesions from nadir.
| months | Arm A: Nab-Paclitaxel + Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| Kaplan-Meier Estimates of Progression-Free Survival (PFS) Based on Investigator Assessment. | 5.5 (4.1 to 7.0) | 8.3 (5.7 to 10.6) | 6.0 (4.7 to 7.2) |
Percentage of participants with an Objective Complete or Partial Overall Response according to RECIST 1.1 and defined as: Complete response-disappearance of all target lesions; partial response at least a 30% decrease in the sum of diameters of target lesions from baseline; stable disease-neither sufficient shrinkage to qualify for PR nor sufficient increase of lesions to qualify for Progressive disease (PD)• Progressive Disease- At least a 20% increase in the sum of diameters of target lesions from nadir.
| percentage of participants | Arm A: Nab-Paclitaxel + Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| Percentage of Participants With an Objective Complete or Partial Overall Response by Investigator Assessment. | 39.3 (27.1 to 52.7) | 73.4 (60.9 to 83.7) | 43.9 (31.7 to 56.7) |
The percentage of participants who initiated Cycle 6 receiving doublet combination therapy regardless of the need for dose modifications.
| percentage of participants | Arm A: Nab-Paclitaxel + Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| Percentage of Participants Who Initiated Cycle 6 Receiving Doublet Combination Therapy | 55.7 (42.5 to 68.5) | 64.1 (51.1 to 75.7) | 50.0 (37.4 to 62.6) |
Overall survival was defined as the time from the date of randomization to the date of death (from any cause).
| months | Arm A: Nab-Paclitaxel + Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| Kaplan-Meier Estimates of Overall Survival | 12.1 (9.4 to 15.9) | 16.8 (11.3 to 20.6) | 12.6 (10.1 to 16.6) |
Treatment-emergent adverse events (TEAEs) were defined as any AEs that began or worsened with the onset date on or after the date of the first dose of IP through 28 days after the last dose. A serious AE (SAE) = any AE which results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; constitutes an important medical event. The severity of AEs was graded based on the participant's symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0); AEs were evaluated for severity as follows: Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening; Grade 5 = Death.
| participants | Arm A: Nab-Paclitaxel + Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| Any TEAE | 60 | 63 | 64 |
| Any Grade 3 or Higher TEAE | 46 | 51 | 54 |
| Treatment-related TEAE | 59 | 62 | 60 |
| Treatment-related, Grade 3 or Higher TEAE | 35 | 43 | 46 |
| Serious TEAE | 22 | 20 | 25 |
| Treatment-related Serious TEAE | 10 | 9 | 13 |
| TEAE Leading to Discontinuation (D/C) of IP | 16 | 29 | 15 |
| Treatment Related (TR) TEAE Leading to D/C of IP | 12 | 27 | 12 |
| TEAE Leading to Dose Reduction (DR) of IP | 23 | 20 | 25 |
| Treatment related TEAE Leading to DR of IP | 23 | 20 | 23 |
| TEAE Leading to Dose Interruption (DI) of IP | 31 | 50 | 50 |
| TR TEAE Leading to DI of IP | 27 | 44 | 44 |
| TEAE leading to D/C of nab-Paclitaxel | 16 | 17 | 0 |
| TR TEAE leading to D/C of nab-Paclitaxel | 11 | 13 | 0 |
| TEAE leading to DR of nab-Paclitaxel | 22 | 19 | 0 |
| TR TEAE leading to DR of nab-Paclitaxel | 21 | 19 | 0 |
| TEAE leading to DI of nab-Paclitaxel | 31 | 50 | 0 |
| TR TEAE leading to DI of nab-Paclitaxel | 27 | 44 | 0 |
| TEAE leading to D/C of Gemcitabine | 13 | 0 | 13 |
| TR TEAE leading to D/C of Gemcitabine | 7 | 0 | 9 |
| TEAE leading to DR of Gemcitabine | 18 | 0 | 25 |
| TR TEAE leading to DR of Gemcitabine | 18 | 0 | 23 |
| TEAE leading to DI of Gemcitabine | 31 | 0 | 49 |
| TR TEAE leading to DI of Gemcitabine | 24 | 0 | 43 |
| TEAE leading to D/C of Carboplatin | 0 | 28 | 15 |
| TR TEAE leading to D/C of Carboplatin | 0 | 25 | 12 |
| TEAE leading to DR of Carboplatin | 0 | 17 | 21 |
| TR TEAE leading to DR of Carboplatin | 0 | 17 | 20 |
| TEAE leading to DI of Carboplatin | 0 | 50 | 50 |
| TR TEAE leading to DI of Carboplatin | 0 | 44 | 43 |
| TEAE Leading to Death | 2 | 1 | 2 |
| Treatment Related TEAE leading to death | 1 | 0 | 1 |
The number of participants with dose modifications occurring during the treatment period. Dose reductions and interruptions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.
| percentage of participants | Arm A: Nab-Paclitaxel + Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| ≥ one DR for both IPs | 33.3 | 46.9 | 51.6 |
| ≥ one DI for both IPs | 38.3 | 70.3 | 73.4 |
| ≥ one dose missed for both IPs | 48.3 | 45.3 | 56.3 |
Treatment-emergent adverse events (TEAEs) were defined as any AEs that begin or worsen with an onset date on or after the date of the first dose of IP through 28 days after the last dose.
| percentage of participants | Arm A: Nab-Paclitaxel + Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| Percentage of Participants Who Discontinued From All Study Treatment Due to TEAEs | 21.7 (12.1 to 34.2) | 26.6 (16.3 to 39.1) | 21.9 (12.5 to 34.0) |
Collected over From randomization through to 28 days after the last dose of IP; up to the data cut-off date of 16 December 2016; AEs collected and monitored for 39 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm A: Nab-Paclitaxel + Gemcitabine | — | 22/60 (36.7%) | 59/60 (98.3%) |
| Arm B: Nab-Paclitaxel + Carboplatin | — | 20/64 (31.3%) | 63/64 (98.4%) |
| Arm C: Gemcitabine + Carboplatin | — | 25/64 (39.1%) | 62/64 (96.9%) |
| Event | Arm A: Nab-Paclitaxel + Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| PyrexiaGeneral disorders | 4/60 | 0/64 | 0/64 |
| PneumoniaInfections and infestations | 4/60 | 1/64 | 1/64 |
| AnaemiaBlood and lymphatic system disorders | 2/60 | 2/64 | 4/64 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/60 | 3/64 | 0/64 |
| NauseaGastrointestinal disorders | 2/60 | 0/64 | 0/64 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 2/60 | 1/64 | 2/64 |
| NeutropeniaBlood and lymphatic system disorders | 1/60 | 2/64 | 2/64 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/60 | 0/64 | 2/64 |
| Non-cardiac chest painGeneral disorders | 0/60 | 0/64 | 2/64 |
| Respiratory tract infectionInfections and infestations | 0/60 | 0/64 | 2/64 |
| Event | Arm A: Nab-Paclitaxel + Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin |
|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 24/60 | 43/64 | 44/64 |
| FatigueGeneral disorders | 33/60 | 32/64 | 24/64 |
| AlopeciaSkin and subcutaneous tissue disorders | 33/60 | 25/64 | 7/64 |
| ThrombocytopeniaBlood and lymphatic system disorders | 8/60 | 18/64 | 34/64 |
| NauseaGastrointestinal disorders | 26/60 | 34/64 | 27/64 |
| AnaemiaBlood and lymphatic system disorders | 25/60 | 33/64 | 30/64 |
| ConstipationGastrointestinal disorders | 13/60 | 27/64 | 25/64 |
| DiarrhoeaGastrointestinal disorders | 25/60 | 26/64 | 13/64 |
| VomitingGastrointestinal disorders | 18/60 | 13/64 | 11/64 |
| Oedema peripheralGeneral disorders | 17/60 | 12/64 | 10/64 |
Intent-to-treat (ITT) population includes all randomized participants regardless of whether they received any IP or had any efficacy assessments collected.
| Age, Continuous(years) | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin | Total |
|---|---|---|---|---|
| Mean | 53.7 ± 12.16 | 54.3 ± 11.96 | 56.7 ± 10.87 | 54.9 ± 11.67 |
| Sex: Female, Male(Participants) | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin | Total |
|---|---|---|---|---|
| Female | 61 | 64 | 66 | 191 |
| Male | 0 | 0 | 0 | 0 |
| Race(Participants) | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin | Total |
|---|---|---|---|---|
| Black or African American | 9 | 6 | 8 | 23 |
| White | 50 | 55 | 54 | 159 |
| Unknown or Not Reported | 2 | 3 | 4 | 9 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin | Total |
|---|---|---|---|---|
| 0 = Fully Active | 34 | 38 | 42 | 114 |
| 1 = Restrictive but ambulatory | 25 | 26 | 22 | 73 |
| 2 = Ambulatory but unable to work | 1 | 0 | 0 | 1 |
| Missing | 1 | 0 | 2 | 3 |
| Disease Free Interval by Clinical Interpretation(Years) | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin | Total |
|---|---|---|---|---|
| ≤ 1 year | 17 | 16 | 20 | 53 |
| > 1 year | 43 | 48 | 45 | 136 |
| Missing | 1 | 0 | 1 | 2 |
| Time from Diagnosis to First Documented Disease/Relapse(months) | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin | Total |
|---|---|---|---|---|
| Mean | 38.8 ± 49.46 | 29.9 ± 37.18 | 50.9 ± 62.60 | 40.0 ± 51.46 |
| Time from First Documented Metastatic Disease/Relapse to Study Randomization(months) | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin | Total |
|---|---|---|---|---|
| Mean | 2.1 ± 5.08 | 4.2 ± 18.39 | 1.6 ± 1.70 | 2.6 ± 11.07 |
| Time from Primary Diagnosis to Randomization(months) | Arm A: Nab-Paclitaxel Plus (+) Gemcitabine | Arm B: Nab-Paclitaxel + Carboplatin | Arm C: Gemcitabine + Carboplatin | Total |
|---|---|---|---|---|
| Mean | 43.7 ± 54.60 | 35.5 ± 40.51 | 52.5 ± 62.37 | 44.0 ± 53.53 |
4 further baseline measures are reported on the registry.
Showing the first 100 of 140 sites across 12 countries. Choose a country and city above to see the rest.
Ran from Sep 2013 to primary completion in Oct 2016, 37 months.
Results were first posted in Mar 2018, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Albumin-Bound Paclitaxel · Carboplatin · Gemcitabine
Triple Negative Breast Neoplasms →